ANKRD16 Inhibitors
ANKRD16 inhibitors are a diverse group of chemical compounds that interact with various cellular pathways to reduce the functional activity of ANKRD16. Staurosporine, a potent kinase inhibitor, targets the ATP binding site common to many kinases, potentially affecting kinase-mediated phosphorylation events crucial for ANKRD16. Similarly, both LY294002 and Wortmannin are PI3K inhibitors that suppress the phosphorylation and activation of downstream pathways, which are likely to have an impact on ANKRD16's role. Compounds like Rapamycin, PD98059, and U0126 are targeted inhibitors of mTOR, MEK, and the MAPK/ERK pathway, respectively, all of which are involved in signaling cascades that could intersect with the function of ANKRD16, especially through modulation of phosphorylation patterns.
In addition to these, SB203580, Alsterpaullone, SP600125, and Lapatinib disrupt various signaling pathways, such as p38 MAP kinase, cyclin-dependent kinases, JNK, and tyrosine kinases like EGFR and HER2/neu. These inhibitors can lead to altered stress responses, cell cycle progression, and growth factor signaling, all of which may indirectly influence ANKRD16 activity. Proteasome inhibitors such as MG132 and Bortezomib cause an accumulation of polyubiquitinated proteins, which can affect protein turnover and regulatory mechanisms pertinent to ANKRD16. These inhibitors collectively provide a framework for understanding the complex regulation of ANKRD16 and offer a biochemical basis for the targeted decrease in its activity through multiple distinct pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent nonspecific protein kinase inhibitor. It inhibits protein kinases by competing for the ATP binding site, which can downregulate kinase-mediated phosphorylation events essential for ANKRD16 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, this compound can reduce the phosphorylation and activation of downstream signaling pathways that could modulate the function of ANKRD16. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a specific mTOR inhibitor, which can lead to the downregulation of protein synthesis pathways that may involve ANKRD16. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the MAPK/ERK pathway. This action can lead to the reduction of phosphorylation events that ANKRD16 may be involved in. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. The inhibition of p38 MAPK can alter the stress response pathways and thus indirectly impact ANKRD16 function. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a cyclin-dependent kinase inhibitor that can halt cell cycle progression. This inhibition can decrease the phosphorylation of proteins potentially interacting with ANKRD16. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the JNK signaling pathway which might alter the phosphorylation status of proteins associated with or regulated by ANKRD16. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can lead to the accumulation of polyubiquitinated proteins, potentially affecting proteins that regulate the stability and function of ANKRD16. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is another proteasome inhibitor which can stabilize proteins that are involved in the degradation or functional regulation of ANKRD16. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K, like LY294002, and it similarly can affect downstream signaling that may modulate ANKRD16's functional interactions. | ||||||